‘Let’s scan ‘em all!’

Article

The Utah Optometric Association is gearing up for a crucial legislative battle over kiosk optical scanning machines.

 

The Utah Optometric Association is gearing up for a crucial legislative battle. Last year UOA was able to defeat a bill titled “Use of Optical Scan Machines,” which sounds benign enough-yet this bill would allow Utahans to obtain an eyeglass (and possibly a contact lens) Rx from an auto-refracting device located in a “kiosk.” State officials fear that  more is to come. 

In an open letter from Clive E. Watson, executive director of the Utah Optometric Association, to other state association executive directors, he states: “With the support of the AOA, the UOA launched a tremendous grass root and lobby effort that prevented this bill from being introduced” during the 2012 session. He continues, “Last year’s sponsor and other key legislators have told us that they think the passing of this legislation is “not a matter of if, but when” (emphasis added). And as Mr. Watson accurately states, “The more broad concern is that if this bill passes in Utah, it will very likely and rapidly expand to include other states in an attempt to become a national standard for eye care delivery.”

The driving force behind this bill may likely 1-800 Contacts, “a formidable, local business darling viewed by many in the Utah legislature as a great success story,” according to Mr. Watson’s letter. “This business is very supportive of Utah legislators and so they are well thought of. Last summer (2012), a large national health insurance provider, WellPoint, purchased 1-800. It should be noted that WellPoint has invested in SoloHealth, a deliverer of health care related “kiosks.” See the thinking here?

People need an eye exam to ensure good ocular health. A refraction is only one small piece of a comprehensive eye exam. How many of us have found serious vision-threatening conditions during “routine eye exams” on patients presenting for “new glasses or contacts?” This is a concern that can affect optometry nationally. Yet it is not just an optometry issue-it is a national public health issue.

To fight what will surely be an expensive legislative battle, the UOA has established the Patients First Defense Fund. “This fund will be managed by leadership of UOA and would only be used to fight ‘kiosk’ related legislation in Utah,” said Mr. Watson in his letter.

The Utah Optometric Association can be reached at (801) 364-9103 or by mail at:

230 West 200 South, Suite 2110
Salt Lake City, UT 84102.

Please consider aiding the UOA in this most important fight not only for the citizens of Utah, but for all our patients.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
© 2025 MJH Life Sciences

All rights reserved.